VanEck JP Morgan EM Local Currency Bond ETF vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $24.84 (market cap $4.93B), while Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B). The key difference: Iovance Biotherapeutics Inc. Common Stock is the larger of the two by market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck JP Morgan EM Local Currency Bond ETF for 38 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.
| EMLC | IOVA | |
|---|---|---|
Market Cap | $4.93B | $6.04B |
Volume | 2,843,860 | 14,805,993 |
Sector | Fixed Income | Health |
52-Week High | $26.59 | $14.82 |
52-Week Low | $24.53 | $1.81 |
Typical Hold Time | 38 Days | 0 Days |
Enterprise Value | — | $5.97B |
Signals from Pluang's Aura AI — not financial advice
EMLC trades at $24.78, showing minimal daily change. The technical outlook is bearish, with moving averages and ADX signaling a downtrend, while oscillators are neutral. Recent news highlights the ETF hitting a 52-week low amid a strengthening U.S. dollar, which pressures emerging market local currency bonds. No fundamental financial ratios are available in the provided data, limiting traditional valuation analysis.
The outlook remains cautious due to macroeconomic headwinds like dollar strength and potential Fed rate hikes. Risks include currency volatility and rising bond yields. Analyst sentiment appears bearish, with the ETF facing challenges in the near term, though diversification benefits in foreign bonds may offer long-term value if conditions stabilize.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →